Pilot and Influencer, Ritu Rathee, talks about how women face more judgement than men when it comes to online platforms, and how you can combat it by remembering that it's only the view through your lens that should be important in your personal journey.
Families of Covid patients are pleading for hospital care as emergency rooms and wards overflow.
Departure comes after Lord’s relationship with property firms faced scrutiny
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AgEagle Aerial Systems, Inc. (NYSE: UAVS) between September 3, 2019 and February 18, 2021, inclusive (the “Class Period”), of the important April 27, 2021 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased AgEagle securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the AgEagle class action, go http://www.rosenlegal.com/cases-register-2037.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) AgEagle did not have a partnership with Amazon and in fact never had any relationship with Amazon; (2) rather than correct the public’s understanding about a partnership with Amazon, defendants were actively contributing to the rumor that AgEagle had a partnership with Amazon; and (3) as a result, defendants’ statements about AgEagle’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the AgEagle class action, go http://www.rosenlegal.com/cases-register-2037.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of APA Corporation f/k/a Apache Corporation (NASDAQ: APA) between September 7, 2016 and March 13, 2020, inclusive (the “Class Period”) of the important April 26, 2021 lead plaintiff deadline. SO WHAT: If you purchased Apache securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Apache class action, go to http://www.rosenlegal.com/cases-register-2040.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Apache intentionally used unrealistic assumptions regarding the amount and composition of available oil and gas in Alpine High; (2) Apache did not have the proper infrastructure in place to safely and/or economically drill and/or transport those resources even if they existed in the amounts purported; (3) these misleading statements and omissions artificially inflated the value of Apache’s operations in the Permian Basin; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Apache class action, go to http://www.rosenlegal.com/cases-register-2040.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827lrosen@rosenlegal.compkim@rosenlegal.comcases@rosenlegal.comwww.rosenlegal.com
Please replace the photo in release dated February 18, 2021, with the accompanying corrected photo.
The Port Commission of the Port of Houston Authority regular monthly meeting is Tues. April 27 at 9:15 a.m., virtually via WebEx webinar.
The Vatican's ambassador to Mexico on Friday said officials three years ago had asked him not to talk about the extreme violence that has swept the country during more than a decade of fighting between drug cartels, so as not to scare away tourists. The envoy, Franco Coppola, made the comments while visiting the town of Aguililla in Michoacan, a frontline of the drug war that has seen some of the heaviest fighting in Mexico this year, forcing families in surrounding villages to abandon their homes. In 2018, during the administration of former President Enrique Pena Nieto, Coppola said government officials had spoken to him about the issue.
Abuse victims claim Telegram's moderators need to do more to tackle misogyny and other forms of hate.
Apollo Healthcare Corp. (TSX: AHC) ("Apollo" or the "Company") is pleased to announce that it has received shareholder approval for all resolutions voted upon at its annual meeting of shareholders held on April 23, 2021 (the "Meeting").
This year's Academy Awards take place on Sunday, with a largely low-key crop of contenders.
The officials said it was important for women be told about that potential risks of the jab.
Tiger Woods posted a photo of himself on crutches on Friday and said his rehab is "coming along" two months after the golf great suffered severe leg injuries when his car careened off a road near Los Angeles and crashed. Woods sustained compound fractures of his tibia and fibula in his right leg in the early morning crash, which required emergency surgery. Woods was not charged with any crime for the one-car wreck.
The Jakarta regional summit will be Min Aung Hlaing's first trip since the army took power in a coup.
"It's time to move on."
The compact SUV now has an all-electric plug-in battery version called E-Tense, which makes it sound a bit more forbidding than it is, writes Sean O’Grady. It doesn’t make you tense, quite the opposite
A Hackney-based photographer’s series stars local strangers, and paints a picture of a diverse community. Jenny Lewis tells Olivia Campbell about finding the extraordinary in the everyday
The biker shorts and sports bras have that second skin feel.
Ronnie O'Sullivan admits he hasn’t enjoyed his snooker for a ‘long time’ after his tilt at Crucible history came to an end, writes Will Jennings.
LONDON, Ontario, April 23, 2021 (GLOBE NEWSWIRE) -- Indiva Limited ("Indiva" or the "Company") (TSX-V: NDVA) (OTCQX: NDVAF) announced today that it may be delayed in filing its annual audited financial statements for the year ended December 31, 2020 and its related Management's Discussion and Analysis and Chief Executive Officer and Chief Financial Officer certifications (the "Required Filings") by the prescribed filing deadline of April 30, 2021. Although the Company and its auditors continue to work diligently toward completing the Required Filings by the filing deadline, the Company has made an application to the Ontario Securities Commission (the "OSC") for a management cease trade order ("MCTO"). If the Company has not made the Required Filings on or before April 30, 2021, the MCTO, if granted, would restrict all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company until the default is remedied. There is no guarantee that an MCTO will be granted. If the MCTO is not issued by the OSC, the applicable Canadian securities regulatory authorities could issue a general cease trade order against the Company for failure to file its annual audited financial statements within the prescribed time period. The Company and its auditors have experienced certain delays in completing year-end accounting and auditing tasks under "work-from-home" mandates as a result of the ongoing COVID-19 pandemic. Indiva is not aware of any specific accounting or audit concerns at this time. Indiva anticipates that, with the potential benefit of additional time and likely no later than May 14, 2021, it will be in a position to complete the Required Filings, including receiving an unqualified audit opinion on the year-end financial statements. The Company intends to comply with the provisions of the alternative information guidelines as set out in the National Policy 12-203 – Management Cease Trade Orders for as long as it remains in default, including the issuance of bi-weekly default status reports in the form of a news release. About Indiva Indiva sets the standard for quality and innovation in cannabis. As a Canadian licensed producer, Indiva creates premium pre-rolls, flower, capsules, and edible products and provides production and manufacturing services to peer entities. In Canada, Indiva produces and distributes the award-winning Bhang® Chocolate, Wana™ Sour Gummies, Ruby® Jewels Chewable Tablets, Ruby® Cannabis Sugar, Sapphire™ Cannabis Salt, Artisan Batch, and other Powered by INDIVA™ products through license agreements and partnerships. Click here to connect with Indiva on LinkedIn, Instagram, Twitter and Facebook, and here to find more information on the Company and its products. For further information, please contact: INVESTOR CONTACTAnthony SimonePhone: 416-881-5154Email: ir@indiva.com DISCLAIMER AND READER ADVISORY Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the contents of this press release and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release. Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Company's ability to file the Required Filings in the time required, dependence upon regulatory approval and the uncertainty of the OSC granting an MCTO, the failure of third parties to comply with their obligations to the Company or its affiliates, risks related to COVID-19, future operations, future results, future product offerings and compliance with applicable regulations. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to obtain and maintain the necessary regulatory and other third parties’ approvals and licensing and other risks associated with regulated entities in the cannabis industry, future sales, the demand for the Company’s products and cannabis products generally and the continued operations of the Company in the ordinary course. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
InterCure is the Most Well-Capitalized Cannabis Company in Israel and is Positioned to Consolidate the Israeli Market and Further Expand Across Europe Combined Company led by Chairman and Former Prime Minister of Israel Ehud Barak and CEO Alex Rabinovitch InterCure has Doubled Revenues Sequentially in Four of the Last Five Quarters; Growth Plans Include Tripling Retail Footprint by 2022 Common Shares of InterCure now Trade on the TSX Under the Symbol “INCR.U” and the TASE Under the Symbol “INCR” Listing of InterCure’s Shares on NASDAQ Expected in Q2 2021 and Will Trade Under the Symbol “INCR” InterCure Filed a Confidential 20-F Registration Statement with the SEC Prior to Closing NEW YORK and TORONTO and HERZLIYA, Israel, April 23, 2021 (GLOBE NEWSWIRE) -- Subversive Acquisition LP (TSX: SVX.U, OTCQX: SBVRF) (“SVX”) a special purpose acquisition company (SPAC), today announced the close of its qualifying transaction to combine with InterCure Ltd. (dba Canndoc) (TASE: INCR), Israel’s leading cannabis company (the “Transaction”). Canndoc, a wholly owned subsidiary of InterCure Ltd., is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products in pharmacies across the country. Canndoc leverages its market leading distribution network, significant logistics infrastructure, best in class international partnerships and a high-margin vertically integrated strategy to be the most profitable cannabis company in Israel and one of the most profitable globally outside of North America. Canndoc has an EBITDA annualized run rate of greater than US$10 million and positive free cash flow. Furthermore, we believe that Canndoc is well-positioned to capitalize on the adult-use market in Israel, which is expected to be legalized in 2021 or 2022. Common Shares of InterCure are now listed for trading on the TSX under the symbol "INCR.U" and will continue to be listed on the TASE under the symbol "INCR." SPAC Restricted Voting Units currently trading on the TSX under the symbol “SVX.U” and on the OTCQX under the symbol “SBVRF” will automatically convert to shares of “INCR.U” on the TSX on a one to one ratio. Effective today, holders of Rights trading under the symbol “SVX.RT.U” will automatically convert to shares of “INCR.U” on an eight to one ratio. InterCure’s NASDAQ listing is expected to occur in Q2 2021 under the symbol “INCR.” InterCure has filed a confidential 20-F registration statement with the Securities and Exchange Commission to facilitate the NASDAQ listing. Michael Auerbach, Founder of Subversive Capital, said, “With this transaction, InterCure has cemented itself as the clear leader in Israel with the ability to now dominate and consolidate the market as the country prepares for an adult-use regime in 2022.” InterCure’s Chairman and former Prime Minister of Israel, Ehud Barak, added, “InterCure continues to pave the way for the global cannabis industry, and we are excited to close this transformative deal. I would like to thank both the InterCure and Subversive teams for their hard work and dedication, and I look forward to creating more shareholder value.” InterCure’s Chief Executive Officer, Alex Rabinovitch, added, “We are proud to announce the closing of this transaction which marks an important milestone for InterCure. With a comprehensive vertically integrated platform, brand portfolio, and the healthiest balance sheet, we are positioned to reshape the cannabis industry in Israel and across Europe.” Management Team – Canndoc will continue to be led by its experienced executive team with deep knowledge of the cannabis industry and operational expertise in the agriculture technology and pharmaceutical industries: Alex Rabinovitch, Chief Executive OfficerAmos Cohen, Chief Financial OfficerRami Levy, Chief Operating OfficerMoshe Gavrilov, Chief Marketing Officer Board of Directors and Medical Advisory Board: Ehud Barak, former Prime Minister of Israel to serve as ChairmanMichael Auerbach, Founder, Subversive Capital (a current board observer who is proposed to become a director upon receipt of the required approval from IMCA)Prof. Zvi Bentwich, MD, PhD, Professor of Microbiology, Immunology, and Genetics, and Head of the Center for Emerging Tropical Diseases & Aids, Ben Gurion UniversityProf. Eitan Friedman, Dir. and Founder Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center InterCure Investment Highlights Proven Business Model – The most profitable company in Israel and one of the most profitable globally outside of North America, growing legal cannabis market with an EBITDA annualized run rate of greater than US$10 million and positive free cash flowFirst Mover Advantage – Significant share of medical market, which grew more than 50% in 2020; First company to import medical grade cannabis to Israel; Positioned to capitalize on the legalization of recreational cannabis locally. Recently announced Letter of Intent to acquire Better positions InterCure as the largest cannabis company outside North America and accelerates international expansion strategy to major markets worldwide.Progressive Operational Platform – Highly profitable, vertically integrated medical cannabis platformKey Partnerships – Canndoc’s exclusive partnerships with leading cannabis brands and suppliers include Cookies, Charlotte’s Web, Aphria, Tilray, Organigram, and moreRobust Balance Sheet to Support Expansion– Cash to drive significant expansion organically and through strategic M&A; Expected expansion of cultivation to over 90 tons per year; Expected to have 10 retail pharmacies by the end of 2021 Investors and security holders may obtain a copy of the final prospectus (the “Prospectus”) associated with the Transaction on InterCure’s website https://www.intercure.co under the Financials & Filings tab, or under the company’s profile on www.sedar.com. Private Placement In connection with the Transaction and in satisfaction of its closing conditions, SVX undertook a private placement of its securities (the “Private Placement”) that were exchanged for common shares of InterCure pursuant to the Transaction. The aggregate amount raised pursuant to the Private Placement was US$50 million which, together with the escrow amount released by SVX’s escrow agent on the closing of the Transaction, satisfied the minimum cash condition contained in the arrangement agreement relating to the Transaction (exceeded the US$55 Million requirement). Subscribers under the Private Placement also received a contractual option to, subject to the receipt of required regulatory approvals, to purchase up to 1,875,000 shares of InterCure, at US$10 per share, exercisable in connection with InterCure’s imminent NASDAQ listing (the “Option”). Redemptions In connection with the closing of the Transaction, holders of SVX’s Restricted Voting Units were provided with a right to redeem their securities (the “Redemption Right”). A total of 8,158,000 Restricted Voting Units were redeemed on closing in connection with the Redemption Right. Advisors Canaccord Genuity Corp. and Cowen Inc. served as financial advisors to SVX. Goodmans LLP, Paul Hastings LLP, and Balter, Guth, Aloni│Ne'eman, Keynan│Granot acted as legal counsel to SVX. Doron Tikotzky Kantor Gutman Nass & Amit Gross served as legal counsel to InterCure. About InterCure (dba Canndoc) InterCure (TSX: INCR.U, TASE: INCR), is the first public company on the Tel Aviv Stock Exchange to hold a valid and permanent license for the medical cannabis value chain through its 100% ownership in Canndoc. Canndoc is a GMP medical cannabis producer. Licensed by the Israeli Ministry of Health since 2008, Canndoc is a leading pioneer in the research, cultivation, production, and distribution of pharma-grade cannabis-based products to patients, hospitals, pharmacies, research and governmental organizations. Through its strategic collaboration with world leaders, distribution agreement with SLE (100% owned by Teva Pharmaceutical Industry), and long-term sales agreements, Canndoc is well-positioned as a leading and significant player in pharma-grade medical cannabis in Israel, Europe, and the United Kingdom. For more information, visit: http://www.intercure.co About Subversive Capital Subversive Capital is a leading investment firm dedicated to investing in radical companies whose core missions subvert the status quo. With almost a decade of experience in the global cannabis industry, Subversive Capital has led investments in some of the most successful transactions in the industry, including the recent launch and closing transaction of Subversive Capital Acquisition Corp. to form The Parent Company (TPCO Holding Corp.) currently traded on the Neo Exchange and OTCQX.For more information, visit www.subversivecapital.com. NON-IFRS MEASURES This press release makes reference to certain non-IFRS financial measures. EBITDA, as defined by SVX and InterCure, means earnings before interest, income taxes, depreciation, and amortization for a quarter annualized. This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. SVX’s and InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. SVX and InterCure use this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company. Forward Looking Statements This press release may contain forward-looking information within the meaning of applicable securities legislation which reflects SVX’s current expectations regarding future events. The words “will”, “expects”, “intends” and similar expressions are often intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specific forward-looking information contained in this press release includes, but is not limited to: statements concerning the NASDAQ listing, the expected operations, financial results and condition of Canndoc following closing of the Transaction, including Canndoc’s financial results, expected management team, business strategy, competitive strengths, goals and expansion and growth plans as well as statements regarding the growth rate of the medical cannabis market. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond SVX’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in the Investor Presentation dated January 26, 2021 and those to be set out in the Prospectus, which is available on SEDAR at www.sedar.com. Subversive Acquisition LP undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Contacts: Subversive CapitalBerrin NoorataBerrin@subversivecapital.com Investor Relationsinvestor@subversivecapital.com InterCure Ltd.Adam Haliva, Global Investor Relationsadam@canndoc-pharma.com, (972) 54-646-8778
Yahoo Finance